Mycophenolate mofetil monitoring: Is there evidence that it can improve outcomes?

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 2, 2011, Pages 204-206

  Byrne, R ^a   Yost, S E ^b   Kaplan, B ^a,c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; TREATMENT OUTCOME;

EID: 79960615103     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.95     Document Type: Review

References (9)

1. Suthakaran, C. & Adithan, C. Therapeutic drug monitoring-concepts, methodology, clinical applications and limitations. Health Administrator 19, 22-26 (2006).
2. van Gelder, T. et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentrationcontrolled trial. Transplantation 86, 1043-1051 (2008).
3. Gaston, R. et al. Fixed-or controlled-dose mycophenolate mofetil with standard-or reduced-dose calcineurin inhibitors: the Opticept Trial. Am. J. Transplant. 9, 1607-1619 (2009).
4. Bullingham, R.E.S., Nicholls, A. & Hale, M. Pharmacokinetics of mycophenolate mofetil: a short review. Transplant. Proc. 28, 925 (1996).
5. Hale, M. et al. The pharmacokineticpharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin. Pharmacol. Ther. 64, 672-683 (1998). (Pubitemid 29011387)
6. Sollinger, H.W.; US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60, 225 (1995).
7. Pawinski, T., Hale, M., Korecha, M., Fitzsimmons, W.E. & Shaw, L.M. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin. Chem. 48, 1497-1504 (2002). (Pubitemid 34925784)
8. Le Meur, Y. et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am. J. Transplant. 7, 2496-2503 (2007). (Pubitemid 47566324)
9. Ekberg, H. et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 357, 2562-2575 (2007). (Pubitemid 350294223)